Literature DB >> 21156649

Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.

James P Hindley1, Cristina Ferreira, Emma Jones, Sarah N Lauder, Kristin Ladell, Katherine K Wynn, Gareth J Betts, Yogesh Singh, David A Price, Andrew J Godkin, Julian Dyson, Awen Gallimore.   

Abstract

A significant enrichment of CD4(+)Foxp3(+) T cells (regulatory T cells, Treg) is frequently observed in murine and human carcinomas. As Tregs can limit effective antitumor immune responses, thereby promoting tumor progression, it is important that the mechanisms underpinning intratumoral accumulation of Tregs are identified. Because of evidence gathered mostly in vitro, the conversion of conventional T cells (Tconv) into Tregs has been proposed as one such mechanism. We assessed the contribution of conversion in vivo by analyzing the TCR (T-cell receptor) repertoires of Tconvs and Tregs in carcinogen-induced tumors in mice. Our results indicate that the TCR repertoires of Tregs and Tconvs within tumor-infiltrating lymphocytes (TIL) are largely distinct. Indeed, the cell population with the greatest degree of repertoire similarity with tumor-infiltrating Tregs was the Treg population from the tumor-draining lymph node. These findings demonstrate that conversion of Tconvs does not contribute significantly to the accumulation of tumor-infiltrating Tregs; rather, Tconvs and Tregs arise from different populations with unique TCR repertoires. Enrichment of Tregs within TILs most likely, therefore, reflects differences in the way that Tregs and Tconvs are influenced by the tumor microenvironment. Elucidating the nature of these influences may indicate how the balance between tumor-infiltrating Tregs and Tconvs can be manipulated for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156649      PMCID: PMC3128990          DOI: 10.1158/0008-5472.CAN-10-1797

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells.

Authors:  Rafal Pacholczyk; Joanna Kern; Nagendra Singh; Makio Iwashima; Piotr Kraj; Leszek Ignatowicz
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

2.  T cell receptor CDR3 sequence but not recognition characteristics distinguish autoreactive effector and Foxp3(+) regulatory T cells.

Authors:  Xin Liu; Phuong Nguyen; Wei Liu; Cheng Cheng; Meredith Steeves; John C Obenauer; Jing Ma; Terrence L Geiger
Journal:  Immunity       Date:  2009-12-10       Impact factor: 31.745

3.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

4.  Cutting edge: size and diversity of CD4+CD25high Foxp3+ regulatory T cell repertoire in humans: evidence for similarities and partial overlapping with CD4+CD25- T cells.

Authors:  Nicolas Fazilleau; Hervé Bachelez; Marie-Lise Gougeon; Manuelle Viguier
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

5.  Adaptation of TCR repertoires to self-peptides in regulatory and nonregulatory CD4+ T cells.

Authors:  Jamie Wong; Reinhard Obst; Margarida Correia-Neves; Grigoriy Losyev; Diane Mathis; Christophe Benoist
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

6.  Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.

Authors:  Andreas Bonertz; Jürgen Weitz; Dong-Ho Kim Pietsch; Nuh N Rahbari; Christoph Schlude; Yingzi Ge; Simone Juenger; Israel Vlodavsky; Khashayarsha Khazaie; Dirk Jaeger; Christoph Reissfelder; Dalibor Antolovic; Maximilian Aigner; Moritz Koch; Philipp Beckhove
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

7.  The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements.

Authors:  Phillip Scheinberg; Jan J Melenhorst; Brenna J Hill; Keyvan Keyvanfar; A John Barrett; David A Price; Daniel C Douek
Journal:  J Immunol Methods       Date:  2007-02-02       Impact factor: 2.303

8.  TCR-based lineage tracing: no evidence for conversion of conventional into regulatory T cells in response to a natural self-antigen in pancreatic islets.

Authors:  Jamie Wong; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2007-08-27       Impact factor: 14.307

9.  A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism.

Authors:  Janine L Coombes; Karima R R Siddiqui; Carolina V Arancibia-Cárcamo; Jason Hall; Cheng-Ming Sun; Yasmine Belkaid; Fiona Powrie
Journal:  J Exp Med       Date:  2007-07-09       Impact factor: 14.307

10.  The impact of regulatory T cells on carcinogen-induced sarcogenesis.

Authors:  G Betts; J Twohig; M Van den Broek; S Sierro; A Godkin; A Gallimore
Journal:  Br J Cancer       Date:  2007-06-12       Impact factor: 7.640

View more
  58 in total

Review 1.  The opposing roles of CD4+ T cells in anti-tumour immunity.

Authors:  Tomasz Ahrends; Jannie Borst
Journal:  Immunology       Date:  2018-04-27       Impact factor: 7.397

Review 2.  Roles of regulatory T cells in cancer immunity.

Authors:  Yoshiko Takeuchi; Hiroyoshi Nishikawa
Journal:  Int Immunol       Date:  2016-05-09       Impact factor: 4.823

Review 3.  Treg Fragility: A Prerequisite for Effective Antitumor Immunity?

Authors:  Abigail E Overacre-Delgoffe; Dario A A Vignali
Journal:  Cancer Immunol Res       Date:  2018-08       Impact factor: 11.151

Review 4.  TGFβ in T cell biology and tumor immunity: Angel or devil?

Authors:  Eric Tu; Pei Zhi Cheryl Chia; Wanjun Chen
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

Review 5.  Nature and nurture in Foxp3(+) regulatory T cell development, stability, and function.

Authors:  Terrence L Geiger; Sharyn Tauro
Journal:  Hum Immunol       Date:  2011-12-27       Impact factor: 2.850

Review 6.  Regulatory T cells in the treatment of disease.

Authors:  Amir Sharabi; Maria G Tsokos; Ying Ding; Thomas R Malek; David Klatzmann; George C Tsokos
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

Review 7.  The effect of environmental chemicals on the tumor microenvironment.

Authors:  Stephanie C Casey; Monica Vaccari; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Mary Helen Barcellos-Hoff; Dustin G Brown; Marion Chapellier; Joseph Christopher; Colleen S Curran; Stefano Forte; Roslida A Hamid; Petr Heneberg; Daniel C Koch; P K Krishnakumar; Ezio Laconi; Veronique Maguer-Satta; Fabio Marongiu; Lorenzo Memeo; Chiara Mondello; Jayadev Raju; Jesse Roman; Rabindra Roy; Elizabeth P Ryan; Sandra Ryeom; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Laura Soucek; Louis Vermeulen; Jonathan R Whitfield; Jordan Woodrick; Annamaria Colacci; William H Bisson; Dean W Felsher
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 8.  Tumor-infiltrating regulatory T cells: origins and features.

Authors:  Guoping Deng
Journal:  Am J Clin Exp Immunol       Date:  2018-10-05

9.  Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors.

Authors:  Tatiana Akimova; Tianyi Zhang; Dmitri Negorev; Sunil Singhal; Jason Stadanlick; Abhishek Rao; Michael Annunziata; Matthew H Levine; Ulf H Beier; Joshua M Diamond; Jason D Christie; Steven M Albelda; Evgeniy B Eruslanov; Wayne W Hancock
Journal:  JCI Insight       Date:  2017-08-17

Review 10.  Ubiquitous points of control over regulatory T cells.

Authors:  Fan Pan; Joseph Barbi
Journal:  J Mol Med (Berl)       Date:  2014-04-29       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.